FindTrial
Sign In

Characteristics of lipid metabolism in patients with severe aplastic anemia and its value in evaluating the efficacy of combined immunosuppressive therapy

Characteristics of lipid metabolism in patients with severe aplastic anemia and its value in evaluating the efficacy of combined immunosuppressive therapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052979
Enrollment
Unknown
Registered
2021-11-07
Start date
2022-07-01
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe aplastic anemia

Interventions

Immunosuppressive therapy group:ATG-based immunosuppression

Sponsors

Zhejiang Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 10 to 60 years; 2. Initial diagnosis, within 3 months after the first chief complaint; 3. Diagnosed as SAA or VSAA, meeting Camitta criteria; 4. Receive IST-based ATG therapy.

Exclusion criteria

Exclusion criteria: Early death (died within 1 months after ATG-based IST), not able to evaluate the treatment efficiency.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy;event-free survival;overall response;Triglyceride;total cholesterol;low-density lipoprotein–cholesterol;high-density lipoprotein–cholesterol;apolipoprotein A;apolipoprotein B;serum immunoglobulin(IgA, IgG, IgM);complement C3, C4;—

Countries

China

Contacts

Public ContactWu Dijiong

Zhejiang Provincial Hospital of Traditional Chinese Medicine

wdj850@163.com+86 571 86620325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026